Final result of the rights issue in Oasmia - Seite 2
The final day for trading in paid subscribed shares (BTA) will be on 16 December 2019. The new shares are expected to start trading on Nasdaq Stockholm on or about 18 December 2019.
Advisors
ABG Sundal Collier is the financial advisor to Oasmia and Hannes Snellman is the legal advisor to Oasmia in connection with the rights issue. Baker McKenzie is the legal advisor to ABG Sundal
Collier in connection with the rights issue.
For more information:
Urban Ekelund, IR Manager Oasmia
Telephone: +46(0)18-50 54 40
E-mail: IR@oasmia.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures and markets new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture
novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and
expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM) and Frankfurt Stock Exchange
(OMAX.GR).
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions and the recipients of this press release in jurisdictions in which this
press release has been released, announced or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press
release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or
subscribe for any securities in Oasmia in any jurisdiction either from Oasmia or from someone else.
Lesen Sie auch
Any investment decision in connection with the rights Issue must be made on the basis of all publicly available information relating to the Company and the Company’s shares. Such information has not been independently verified by ABG Sundal Collier. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.